Antibiotic Use Does Not Appear to Influence Response to Nivolumab
- 29 May 2017
- journal article
- research article
- Published by Anticancer Research USA Inc. in Anticancer Research
- Vol. 37 (6), 3195-3200
- https://doi.org/10.21873/anticanres.11680
Abstract
Background: Microbiota is known to influence response to anticancer immunotherapy. We examined whether antibiotic usage could impact nivolumab efficacy in patients treated for non-small-cell lung cancer (NSCLC). Patients and Methods: Seventy-four patients with NSCLC were included in this retrospective study. They received nivolumab between 2015 and 2016 (3 mg/kg i.v. q2w). The association between RECIST response and antibiotic usage was determined using Chi-square and Cox proportional hazard model. Results: A total of 17, 21 and 36 patients experienced response, stable disease and progression disease under nivolumab. Only 15 (20.3%) patients were exposed to antibiotic medication in the 3 months before the first nivolumab injection or during treatment. We found a similar response rate for the two populations, without impact of antibiotic exposure (Chi-square test p=0.75). Moreover, we observed no impact of antibiotic medication on progression-free survival under nivolumab (log-rank test, p=0.72). Conclusion: Microbiota modification induced by antibiotics does not appear to affect the efficacy of nivolumab in patients with NSCLC.Keywords
This publication has 18 references indexed in Scilit:
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Cancer Statistics, 2015CA: A Cancer Journal for Clinicians, 2014
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- Gut microbiome and anticancer immune response: really hot Sh*t!Cell Death & Differentiation, 2014
- The Intestinal Microbiota Modulates the Anticancer Immune Effects of CyclophosphamideScience, 2013
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor MicroenvironmentScience, 2013
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating ImmunosurveillanceImmunity, 2013
- Interactions Between the Microbiota and the Immune SystemScience, 2012
- Treatment Paradigms for Patients with Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-LineCurrent Oncology, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009